

REVIEW ARTICLE

A review on plants having Anti- *Mycobacterium tuberculosis* Potential

Shweta Sharma¹, Vishal Khandelwal^{2*}

¹Department of Biochemistry, National JALMA Institute for Leprosy & Other Mycobacterial Diseases (ICMR), Tajganj, Agra 282004, Uttar Pradesh, India

^{2*}Department of Biotechnology, GLA University, Mathura-281406, UP, India
Corresponding author- vishal_k80@rediffmail.com

ABSTRACT

Tuberculosis (TB) is a disease that has affected mankind from very ancient time, and caused by Mycobacterium tuberculosis. Plants are an important source of biologically active secondary metabolites which have enormous therapeutic potential. In this review, medicinal plants have shown active against TB with their minimum inhibitory concentration (MIC), which is evaluated by microplate alamar blue assay (MABA) and resazurin microtiterplate assay (REMA) methods. This review work helps in use of medicinal plant to treatment of TB, and decrease the emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR).

Keywords: Tuberculosis, Anti-TB activity, plant.

Received 21.04.2020

Revised 11.06.2020

Accepted 21.08.2020

How to cite this article:

S Sharma, V Khandelwal. A review on plants having Anti- *Mycobacterium tuberculosis* Potential. Adv. Biores., Vol 11 (5) September 2020: 162-165

INTRODUCTION

Tuberculosis (TB) is an infectious disease caused predominantly by *Mycobacterium tuberculosis* (Mtb), has plagued human since antiquity. It is most commonly transmitted by inhalation of aerosols and droplet nuclei which are discharged in the air when a TB patient coughs and sneezes. TB disease usually affects the lungs but can be migrate to any part of the body. Tuberculosis can affect the lymph nodes, pleura, bones & joints, the genitor-urinary tract, the nervous system, abdominal tuberculosis [1]. In 2018, the World Health Organization estimated that there were 10 million TB cases worldwide. There was an estimated 1.2 million (range 1.1-1.3 million) TB death among HIV positive people in 2018, and an additional 251000 deaths (range, 223000-281000) 3 among HIV positive people (60% reduction from 620000 in 2000) [2].

Drug-resistant TB continues to be a public health threat. In 2018 there were about half a million new cases 5 of rifampicin-resistant TB (of which 78% had multidrug resistant TB). The three countries with the largest share of the global burden were India (27%), China (14%) and the Russian Federation (9%) [2].

First line drugs are essential, most effective and necessary component of short course treatment for TB. TB can be treated effectively by using first line drugs Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), Ethambutol (EMB) and Streptomycin (SM). Second line drugs are clinically less effective than first-line drugs and also have some severe side-effects. TB can be treated effectively by using second line drugs, Fluoroquinolones (FQs), Amikacin (AMK), Capreomycin (CAP), Ethionamide/prothionamide (ETH), p-Amino Salicylic Acid (PAS) and Cycloserine (CS). MDR-TB can be raised when the first-line drugs are misused or mismanaged, inappropriate treatment, inadequate drug quality and supply. XDR-TB is defined as MDR-TB that is resistant to quinolones and any one of the injectable such as kanamycin or amikacin [2].

The treatment of TB necessitates complex drug regimens, with adverse effects and interactions, and is associated with poor patient compliance of multidrug-resistant (MDR-TB) and extensively drug-resistant

(XDR-TB) strains. Patients with MDR or XDR-TB require a lengthy course of a combination of drugs that are more expensive, more toxic, and not always effective. Current anti-TB therapy, consist of multiple drugs and involves a lengthy regimen associated with significant risk for the generation of drug-resistant organisms[3]. Furthermore, these lengthy anti-TB therapy exhibit hepatic toxicity. Keeping the aforesaid facts in view, new and effective alternatives for the treatment of TB are urgently needed and in this context, medicinal plants are representing a potential against TB.

In recent year, there has been an increasing interest in natural product based medicines from plant origin. The plants are an important source of biologically active secondary metabolites which have enormous therapeutic potential. World Health Organization (WHO) estimates that about 80% of population living in Africa, and 40% of the population from china are using plant based traditional medicines (TM) for their primary health care needs. In many countries, TM continues to be widely used, even though allopathic medicine is often readily available (World Health Organization 2002-2005). The medicinal plants are back bone of TM and around 3300 million people in the under developed countries utilized medicinal plants on a regular basis. Products of natural origin contain a unique pool of incredibly chemically diverse molecules that have specifically evolved to interact with biological targets and have already provided some invaluable leads for drug design. Plants- based medicines, in particular, are widely by traditional healers in different parts of the world, including for the treatment of TB and TB related symptoms [4], [5], [6].

TRADITIONAL MEDICAL KNOWLEDGE

Medicinal plants, since ancient time, have been used effectively in all cultures as source of medicine. The common use of herbal therapies and healthcare arrangements, as those defined in ancient texts such as the Vedas and the Bible and obtained from commonly used traditional herbs and medicinal plants, has been traced to the occurrence of natural products with medicinal properties [7], [8].

Ayurveda, means the science of life (Ayur = Life, Veda = Science), is an ancient medical knowledge which was developed in India thousands of years ago and describes numerous plants to treat several diseases. Traditional knowledge of herbal medicine can serve as a powerful approach to drug discovery. Plants are an important source of medicines for indigenous people and have a highly significant role in indigenous pharmacopoeias. These are easily available to all tribal peoples of the forest areas. The World Health Organization reported that 80% of world's population depends on traditional medicine, and a major part of the traditional therapies involve the use of plant extracts or their active constituents [9], [10].

Medicinal plants have shown activity against TB with their minimum inhibitory concentration (MIC), which is evaluated by microplate alamar blue assay (MABA) and resazurin microtiter plate assay (REMA) methods, list is given below.

Table1: Antimycobacterial activity of plants extract against *Mycobacterium tuberculosis*

| Plant Name | Family | Part use | Traditional uses of plants | Extract | MIC ($\mu\text{g/ml}$) against TB | References |
|--------------------------------|----------------|-------------|--|------------------------------|-------------------------------------|------------|
| <i>Allium sativum</i> | Liliaceae | Bulb | Effective against bacterial, viral, fungal and parasitic infection | Aqueous | 1.95 | [11] |
| <i>Plumbago zeylanica</i> | Plumbaginaceae | Root | Cough, TB, swelling and ulcer | Ethanollic | 31.25 | [12] |
| <i>Sphaeranthus indicus</i> | Asteraceae | Floral head | Chest complaints and dysentery | Ethanollic | 31.25 | [13] |
| <i>Ocimum basilicum</i> | Lamiaceae | Seeds | Antibacterial, Antiviral, and Antifungal | 80% Methanol | 25 | [14] |
| <i>Cyperus rotundus</i> | Cyperaceae | Root | Chest complaints, prolonged cough and fever | Ethanollic | 62.5 | [15] |
| <i>Aegle marmelos</i> | Rutaceae | Leaves | Anti-inflammatory | Hexane, acetone and methanol | 100 | [16] |
| <i>Calophyllum brasiliense</i> | Clusiaceae | Leaves | Antibacterial | Dichloromethane and aqueous | 125 | [17] |

| | | | | | | |
|-----------------------------------|----------------|----------------|---|------------|--------|----------|
| <i>Curcuma caesia</i> | Zingiberaceae | Rhizome | Chest complaints, cold and TB | Ethanollic | 125 | [18] |
| <i>Stachytarpheta cayennensis</i> | Verbenaceae | Leave and root | Antibacterial | Aqueous | >200 | [19] |
| <i>Glycyrrhiza glabra</i> | Fabaceae | Root | Cold, cough, sore throat, TB and leprosy | Ethanollic | 250 | [6],[19] |
| <i>Holarrhena antidysenterica</i> | Apocynaceae | Seeds | Chest complaints, prolonged cough and leprosy | Ethanollic | 250 | [20] |
| <i>Mallotus philippensis</i> | Euphorbiaceae | Fruits | Chest complaints, TB, leprosy and wounds | Ethanollic | 250 | [6] |
| <i>Alstonia scholaris</i> | Apocynaceae | Bark | Chest complaints, fever and TB | Ethanollic | 500 | [21] |
| <i>Cocculus hirsutus</i> | Menispermaceae | Leaves | Chest complaints, prolonged cough and leucorrhoea | Ethanollic | 500 | [22] |
| <i>Pueraria tuberosa</i> | Fabaceae | Tuber | Prolonged cough, and urinary troubles | Ethanollic | 500 | [18] |
| <i>Eulophia nuda Lindl</i> | Orchidaceae | Tubers | Chest complaints, and snake bite | Ethanollic | 500 | [22] |
| <i>Adhatoda vasica</i> | Acanthaceae | Leaves | Use in Asthma | Aqueous | 2% v/v | [23] |

CONCLUSION

Traditional knowledge and the use of plant-based medicines remain important in the prevention and treatment of disease. This is important because the traditional medicine is often quickly accessible and affordable to the rural communities. The emergence and spread of MDR strains around the world is making TB control a difficult task. This review makes an attempt to give scientific account to use of medicinal plant extract in tuberculosis treatment.

REFERENCES

1. Revised National TB Control programme. (2019).
2. WHO, Global TB Report. (2019).
3. Plalomino, J.C., Ramos, D.F., da Silva, P.A. (2009) New anti-tuberculosis drugs: strategies, sources and new molecules. *Curr. Med. Chem.*, 16, 1898-1904.
4. Copp, B.R., Pearce, A.N. (2007) Natural product growth inhibitors of *Mycobacterium tuberculosis*. *Nat. Prod. Rep.*, 24, 278-297.
5. Santhosh, R.S., Suriyanarayanan, B. Plants: a source for new antimycobacterial drugs. *Plants Med.*, 80, 9-21.
6. Gupta, V.K., Kaushik, A., Chauhan, D.S., Ahirwar, R.K., Sharma, S., Bisht, D. (2018) Antimycobacterial activity of some medicinal plants used traditionally by tribes from Madhya Pradesh, India for treating TB related symptoms. *J. Ethnopharmacology*, 227, 113-120.
7. Arya, V. (2011) A review on anti-Tuberculosis plants. *Int. J. PharmaTech. Res.*, 3(2), 872-880.
8. Berdy, J. (2001) Bioactive microbial metabolites. *J. Antibiot (Tokyo)*, 58, 1-26.
9. Rates, S.M. (2001) Plants as source of drugs. *Toxicon*, 39(5), 603-613.
10. Samy, R.P., Pushparaj, P.N., Gopalkrishnakone, P. (2008) A compilation of bioactive compounds from Ayurveda. *Bioinformation*, 3(3), 100-100.
11. Viswanathan, V., Phadatare, A.G., Mukne, A. (2014) Antimycobacterial and antibacterial activity of *Allium sativum* bulbs. *Indian J Pharm Sci*, 76(3), 256-61.
12. Tilak, J.C., Adhikari, S., Devasagayam, T.P. (2004) Antioxidant properties of *Plumbago zeylanica*, an Indian medicinal plant and its active ingredient, plumbagin. *Redox Rwp.*, 9, 219-227.
13. Galani, V.J., Patel, B.G., Rana, D.G. (2010) *Sphaeranthus indicus* Linn: a phytopharmacological review. *Int. J. Ayurveda Res.*, 1(4), 247-253.
14. Balcha, E., Mengiste, B., Gebrelibanos, M., Worku, A. G. (2014) Evaluation of in vitro antimycobacterial activity of selected medicinal plants in Mekelle. *Ethiopia World Appl Sci. J.*, 31, 1217-1220.
15. Srivastava, R.K., Singh, A., Shukla, S.V. (2013) Chemical investigation and pharmaceutical action of *Cyperus rotundus*- a review. *J. Biol. Act. Prod. Nat.*, 3(3), 166-172.
16. Kaur, R., Kaur, H. (2015) Antitubercular activity and phytochemical screening of selected medicinal plants. *Orient J. Chem.*, 31, 597-600.
17. Pires, C.T., Brenzan, M.A., Scodro, R.B., Cortez, D.A., Lopes, L.D., Siqueira, V.L. (2014) Antimycobacterial tuberculosis activity and cytotoxicity of *Calophyllum brasiliense* Cambess (Clusiaceae). *Mem. Inst Oswaldo Cruz*, 109(3), 324-9.
18. Pandey, D., and Gupta, A.K. (2014) Antibacterial efficacy of *Curcuma caesia* from Bastar District of Chhattisgarh India. *Int. J. Pharma. Sci. Res.*, 5(6), 2294-2301.

Sharma and Khandelwal

19. Tiwari, B., Shailajan, S., Menon, S., and Kulkarni, S. (2019) Tuberculosis: History, Epidemiology, Antitubercular Drugs and Plant based Alternatives. *India J. PharmaSci*,81(2), 200-210
20. Jamadagni, P.S., Pawar, S.D., Jamadagni, S.B., Chougule, S., Gaidhani, S.N. (2017) Review of *Holarrhena antidysenterica* (L.) wall. ex A. DC: Pharmacognostic, Pharmacological, and toxicological perspective. *Pharmacogn. Rev*, 11(22), 141-144.
21. Antony, M., James, J., Mishra, C.S., Sagadevan, L.D.M., Veetil, A.K.T., Thankamani, V. (2014) Antimycobacterial activity of the plant extracts of the *Alstonia scholaris*. *Int. J. Curr. Pharm. Res*, 2014, 40-42.
22. Khare, C.P. (2007) *Indian Medicinal Plants. An illustrated Dictionary*. Springer- Verlag, Berlin/Heidelberg.
23. Gupta, R., Thakur, B., Singh, P., Singh, H.B., Sharma, V.D., Katoch, V.M. (2010) Anti-tuberculosis activity of selected medicinal plants against multi drug resistant *Mycobacterium tuberculosis* isolates. *Indian J Med Res.*, 809- 813.

Copyright: © 2020 Society of Education. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.